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Background
Plasmacytoid dendritic cells (PDCs) have been described
to link innate and adaptive immunity. Indeed, these cells
are able to capture and present antigens, and produce high
amounts of cytokines, especially antiviral type I interfer-
ons. PDCs are productively infected by HIV in vitro and in
vivo, and several studies have shown a decrease in circulat-
ing PDCs number that was correlated with an increase of
plasma viral load. However, the inhibitory effect of neu-
tralizing antibodies on PDCs infection has not been yet
assessed.
Methods
We first compared primary PDCs purified either by posi-
tive selection or by depletion from peripheral blood
mononuclear cells of healthy donors. Then, using flow
cytometry, the percentage of infected PDCs was deter-
mined by the detection of p24-positive BDCA-2+CD123+
cells. We also tested a recently described PDC GEN2.2 cell
line for HIV infection.
Results
After depletion, the subset of PDCs expressing FcγRII cor-
responding to 30–50% of total PDCs population was not
recovered. This lack of FcγRII+ PDCs hamper the study of
FcγRII mediated inhibitory activity by non-neutralizing
inhibitory antibodies. Therefore, PDCs isolated with
BDCA-4 positive selection were used to study the inhibi-
tion of PDCs infection by the HIV. Preliminary data indi-
cated that neutralizing antibodies were able to efficiently
inhibit primary PDCs infection.
We found that PDC GEN2.2 cell line was productively
infected by R5 HIV primary isolates. Neutralization study
performed on this cell line demonstrated a neutralizing
profile similar to primary PDCs.
Conclusion
Preventing PDCs infection by the induction of efficient
HIV-specific antibodies should be one of the goals in HIV
vaccine development in order to maintain the PDCs anti-
viral function during acute infection.
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